Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis

Neurology

Volumn 84, Issue 22, 2015, Pages 2247-2257

  Lu, Ching Hua ^a,b   Macdonald Wallis, Corrie ^c   Gray, Elizabeth ^d   Pearce, Neil ^e   Petzold, Axel ^b   Norgren, Niklas ^f   Giovannoni, Gavin ^a   Fratta, Pietro ^b   Sidle, Katie ^b   Fish, Mark ^g   Orrell, Richard ^b,h   Howard, Robin ^h   Talbot, Kevin ^d   Greensmith, Linda ^b   Kuhle, Jens ^a,i   Turner, Martin R ^d   Malaspina, Andrea ^a,h,j,k  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f UmanDiagnostics AB   (Sweden)

^g MUSGROVE PARK HOSPITAL   (United Kingdom)

^h NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL BASEL   (Switzerland)

^j North East London and Essex MND Care and Research Centre   (United Kingdom)

^k BASILDON HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN L;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BLOOD LEVEL; CEREBROSPINAL FLUID LEVEL; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; NEUROFILAMENT; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; BLOOD; CEREBROSPINAL FLUID; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; FOLLOW UP; LONGITUDINAL STUDY; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; BIOMARKERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROFILAMENT PROTEINS; PROGNOSIS;

EID: 84930342939     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001642     Document Type: Article

References (32)

1. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005;233:183-198.
2. Brettschneider J, Petzold A, Sussmuth SD, Ludolph AC, Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 2006;66:852-856.
3. Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res 2003; 987:25-31.
4. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996;67: 2013-2018.
5. Reijn TS, Abdo WF, Schelhaas HJ, Verbeek MM. CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol 2009;256:615-619.
6. Lehnert S, Costa J, de Carvalho M, et al. Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:344-350.
7. Lu CH, Kalmar B, Malaspina A, Greensmith L, Petzold A. A method to solubilise protein aggregates for immunoassay quantification which overcomes the neurofilament "hook" effect. J Neurosci Methods 2011;195:143-150.
8. Lu CH, Petzold A, Topping J, et al. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. J Neurol Neurosurg Psychiatry Epub 2014 Jul 9.
9. Gaiottino J, Norgren N, Dobson R, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One 2013;8:e75091.
10. Tortelli R, Copetti M, Ruggieri M, et al. Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis. Eur J Neurol 2015;22:215-218.
11. Tortelli R, Ruggieri M, Cortese R, et al. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol 2012;19: 1561-1567.
12. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293-299.
13. Petzold A, Keir G, Kay A, Kerr M, Thompson EJ. Axonal damage and outcome in subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2006;77:753-759.
14. Petzold A, Mondria T, Kuhle J, et al. Evidence for acute neurotoxicity after chemotherapy. Ann Neurol 2010;68: 806-815.
15. Petzold A, Tisdall MM, Girbes AR, et al. In vivo monitoring of neuronal loss in traumatic brain injury: a microdialysis study. Brain 2011;134:464-483.
16. Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009;73:1914-1922.
17. Leckie G, Charlton C. Runmlwin: a program to run the MLwiN multilevel modeling software from within Stata. J Stat Softw 2013;52:1-40.
18. Touloumi G, Pocock SJ, Babiker AG, Darbyshire JH. Estimation and comparison of rates of change in longitudinal studies with informative drop-outs. Stat Med 1999; 18:1215-1233.
19. Cnaan A, Laird NM, Slasor P. Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med 1997;16:2349-2380.
20. Berry JD, Miller R, Moore DH, et al. The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:162-168.
21. Rudnicki SA, Berry JD, Ingersoll E, et al. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a phase II study: subgroup analysis of demographic and clinical characteristics. Amyotroph Lateral Scler Frontotemporal Degener 2013;14: 44-51.
22. Fialova L, Svarcova J, Bartos A, et al. Cerebrospinal fluid and serum antibodies against neurofilaments in patients with amyotrophic lateral sclerosis. Eur J Neurol 2010; 17:562-566.
23. Puentes F, Topping J, Kuhle J, et al. Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2014; 85:274-278.
24. Shahim P, Tegner Y, Wilson DH, et al. Blood biomarkers for brain injury in concussed professional ice hockey players. JAMA Neurol 2014;71:684-692.
25. Lu CH, Petzold A, Kalmar B, Dick J, Malaspina A, Greensmith L. Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1 G93A mice that model ALS. PLoS One 2012;7:e40998.
26. Ganesalingam J, Bowser R. The application of biomarkers in clinical trials for motor neuron disease. Biomark Med 2010;4:281-297.
27. Kuhle J, Gaiottino J, Leppert D, et al. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. J Neurol Neurosurg Psychiatry 2015;86:273-279.
28. Turner MR, Agosta F, Bede P, Govind V, Lule D, Verstraete E. Neuroimaging in amyotrophic lateral sclerosis. Biomark Med 2012;6:319-337.
29. Hye A, Riddoch-Contreras J, Baird AL, et al. Plasma proteins predict conversion to dementia from prodromal disease. Alzheimers Dement 2014;10:799-807.e2.
30. Mousavi M, Jonsson P, Antti H, et al. Serum metabolomic biomarkers of dementia. Dement Geriatr Cogn Dis Extra 2014;4:252-262.
31. Forsberg A, Almkvist O, Engler H, Wall A, Langstrom B, Nordberg A. High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res 2010;7:56-66.
32. Benatar M, Wuu J, Ravits J. Opportunity and innovation in studying pre-symptomatic amyotrophic lateral sclerosis. Muscle Nerve 2013;47:629-631.